{"filing":{"accession_number":"0001818382-26-000011","cik":"0001818382","ticker":"HUMAW","company_name":"Humacyte, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-22","primary_document":"huma-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838226000011/huma-20260922.htm"},"events":[{"id":35431,"run_id":32632,"accession_number":"0001818382-26-000011","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Humacyte appointed Scott Coward and Paul Kuznik to its Board of Directors on September 22, 2026. Both appointees bring substantial experience in life sciences commercialization and enterprise leadership relevant to the company's commercial-stage biotech operations and planned product launches.","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39471,"accession_number":"0001818382-26-000011","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two directors, Scott Coward and Paul Kuznik, to Humacyte's Board on September 22, 2026. Both bring substantial experience in life sciences, commercialization, and enterprise leadership relevant to the company's commercial-stage biotech operations. This is a material governance event affecting board composition and oversight during a critical period as the company prepares for commercial launches of its ATEV product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:10:21.262472+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39472,"accession_number":"0001818382-26-000011","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Scott Coward and Paul Kuznik to Humacyte's Board of Directors, announced via press release on September 28, 2026. Both appointees bring substantial experience in commercialization, enterprise leadership, and life sciences—directly relevant to the company's ongoing Symvess® launch and planned ATEV commercial launch in dialysis access. Board appointments of individuals with material operational expertise are material governance events affecting investor assessment of leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:10:21.262472+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39471,"accession_number":"0001818382-26-000011","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two directors, Scott Coward and Paul Kuznik, to Humacyte's Board on September 22, 2026. Both bring substantial experience in life sciences, commercialization, and enterprise leadership relevant to the company's commercial-stage biotech operations. This is a material governance event affecting board composition and oversight during a critical period as the company prepares for commercial launches of its ATEV product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:10:21.262472+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-09-28"},{"id":39472,"accession_number":"0001818382-26-000011","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Scott Coward and Paul Kuznik to Humacyte's Board of Directors, announced via press release on September 28, 2026. Both appointees bring substantial experience in commercialization, enterprise leadership, and life sciences—directly relevant to the company's ongoing Symvess® launch and planned ATEV commercial launch in dialysis access. Board appointments of individuals with material operational expertise are material governance events affecting investor assessment of leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:10:21.262472+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-09-28"}]}